Altrius Capital Management Inc Has $4.38 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Altrius Capital Management Inc trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 24.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 47,402 shares of the biopharmaceutical company’s stock after selling 15,005 shares during the quarter. Altrius Capital Management Inc’s holdings in Gilead Sciences were worth $4,379,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in the company. HHM Wealth Advisors LLC increased its stake in Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 154 shares during the period. YANKCOM Partnership bought a new stake in Gilead Sciences in the fourth quarter worth approximately $28,000. Decker Retirement Planning Inc. acquired a new position in shares of Gilead Sciences during the 4th quarter worth $29,000. Valued Wealth Advisors LLC lifted its stake in shares of Gilead Sciences by 101.9% in the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 161 shares during the last quarter. Finally, Crews Bank & Trust acquired a new position in Gilead Sciences during the fourth quarter worth $31,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the transaction, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. This represents a 1.89 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last three months, insiders have sold 293,356 shares of company stock valued at $29,166,240. 0.16% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of brokerages have weighed in on GILD. Morgan Stanley boosted their price target on Gilead Sciences from $113.00 to $123.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 12th. Wolfe Research started coverage on Gilead Sciences in a research report on Friday, November 15th. They set an “outperform” rating and a $110.00 target price for the company. Maxim Group cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Bank of America reiterated a “buy” rating and issued a $109.00 target price on shares of Gilead Sciences in a report on Tuesday, December 10th. Finally, Citigroup initiated coverage on Gilead Sciences in a research report on Thursday, November 14th. They issued a “buy” rating and a $125.00 price target on the stock. Eleven investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $102.08.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock opened at $111.99 on Friday. The company has a 50-day simple moving average of $96.98 and a two-hundred day simple moving average of $89.65. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $112.57. The stock has a market capitalization of $139.57 billion, a price-to-earnings ratio of 302.68, a price-to-earnings-growth ratio of 0.71 and a beta of 0.18. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be given a dividend of $0.79 per share. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a dividend yield of 2.82%. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences’s dividend payout ratio is currently 854.05%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.